04/02/2022at 09:33

Ambu's Ascope Gastro and Abox 2 approved by FDA

Two new products can be sent to the US market after Ambu has received the green light from the US health authorities.

by marketwire, translated by daniel pedersen

Ambu has been granted regulatory clearance from the US Food and Drug Administration for its single-use endoscope, Ascope Gastro, and the display unit, Abox 2, the company announces in a press release on Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Ambu wins single-use endoscope contract with US healthcare service giant
For subscribers
Ambu launches two new endoscope carts
For subscribers
Boston Scientific's endoscope business grows by over 20 percent
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

Other

Production at contaminated CMO continues – authorities deny further risks

For subscribers

Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

Pharma & biotech

Indian generic drugmaker to launch Leo Pharma copycat drug in US

For subscribers

Regulation

EU delays new drug law proposal

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

For subscribers

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.

For subscribers

Foto: Christopher Due Karlsson / MedWatch

Pharma & biotech

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

The very top of the Danish drugmaker has only grown more distant to its own goal of ensuring 45% male/female representation across leadership teams.

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Ambu's Ascope Gastro and Abox 2 approved by FDA

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Ambu wins single-use endoscope contract with US healthcare service giant

Ambu launches two new endoscope carts

Boston Scientific's endoscope business grows by over 20 percent

Sign up for our newsletter

Front page now

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Production at contaminated CMO continues – authorities deny further risks

Indian generic drugmaker to launch Leo Pharma copycat drug in US

EU delays new drug law proposal

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Novo Nordisk enters collaboration with AI-driven drug discovery company

Further reading

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Jobs